Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.
Vibeke Strand, MD, MACR, FACP, Division of Immunology and Rheumatology, Stanford University, conducted a study on the effect of secukinumab in patients with active psoriatic arthritis (PsA). In an interview with HCPLive®, she explained that even treatment-resistant patients showed significant improvement.
The Phase 3 study included patients who were naive to tumor necrosis factor (TNF) inhibitor, as well as patients who were TNF-inadequate or TNF-incomplete responders.
Strand said that this extensive dataset gives a comprehensive overview of secukinumab, which is just one of the various treatment options that healthcare providers have to treat their patients with psoriatic arthritis.
"So, part of this analysis was to really help healthcare providers to understand what this particular IL-17 can do, and where they might want to fit it into their treatment armamentarium," Strand said. "So, in other words, it's never too late to use it, but you can also use it early. And you'll see extensively more benefit in patients with shorter disease duration and less treatment failures."